Natco Pharma Share Price Target 2024 To 2030 – Natco Pharma Limited is an Indian multinational pharmaceutical company which is based in Hyderabad, Telangana. The company was started in 1981 and has specialization in the formulation and manufacturing as well as marketing of formulations and APIs. Natco has a considerable market penetration in the generics segment especially in oncology, cardiology and CNS therapeutic segment.
The company has multiple manufacturing facilities within India and has an international presence, exporting its products to more than forty countries across the world. Natco also has the right approach towards quality and compliance; the company assures that its products are compliant with various markets across the world.
Natco Pharma Share Price Current Market Overview
- Open: 1550.30
- High: 1550.30
- Low: 1530.10
- Current Share Price: 1555.90
- Market Capital: 27.54K Cr
- P/E: 16.83
- Dividend Yield: 0.36%
- 52 Week High: 1584.95
- 52 Week Low: 724.20
Natco Pharma Share Price Recent Graph
Share Price Target Tomorrow From 2024 To 2030
Here are the details regarding the share price target of Natco Pharma Limited for upcoming years. This data is based on expert analysis, market valuation, and industrial trends.
| S. No. | Share Target Price Years | Share Target Value |
|
|
2024 | 2065.03 |
|
|
2025 | 2410 |
|
|
2026 | 2745 |
|
|
2027 | 3125 |
|
|
2028 | 3562 |
|
|
2029 | 4102 |
|
|
2030 | 4685 |
Shareholding Pattern For Natco Pharma
- Promoters: 49.71%
- Retail & Others: 24.97%
- Foreign Institutions: 17.45%
- Other Domestic Institutions: 5.20%
- Mutual Funds: 2.67%
Natco Pharma Annual Income Statement
The given shows the comparison between the revenue and net income of Natco Pharma Limited.
For detailed information regarding the annual income statement, go through the given table.
| Particulars | Info 2024 | Y/Y Change |
| Revenue | 41.27B | 52.37% (+) |
| Operating Expenses | 17.18B | 38.04% (+) |
| Net Income | 13.88B | 94.09% (+) |
| Net Profit Margin | 33.64 | 27.38% (+) |
| Earning Per Share | 77.34 | 97.40% (+) |
| EBITDA | 18.80B | 94.38% (+) |
| Effective Tax Rate | 17.04% | N/A |
Challenges For Natco Pharma Share Price
Patent Litigations And Legal Risks
There is always a likelihood that current and future patent lawsuits may hamper the launch of generic products, thus hurting the revenue and potential investor returns.
Regulatory Challenges
The implementation of intensive regulatory requirements in most of the markets anywhere in the world, particularly in the United States and European countries, affects the approval and entry of its products into the market.
Pricing Pressure
High levels of competitive forces in the market imply that the prices of these generics may down and hence the profit margin will be cut down.
Currency Fluctuations
Since a part of its revenues is earned in foreign currencies, exchange rate volatility also creates an unfavourable situation.
